Altimmune Inc. (ALT)
NASDAQ: ALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $258.80M
- EPS (TTM)
- -$0.71
- Dividend yield
- None
- 52-week range
- 1.32 – 6.44
- Day range
- 1.32 – 1.46
- Volume / Avg
- 4.02M / 3.91M
- Beta
- —
- Shares outstanding
- 194.59M
52-week range
ALT stock today
On Nov 20, ALT ended the session at $1.33, shedding $0.08 (5.67%), versus the S&P 500's 3.70% decline. Shares are 79.3% below their 52-week high of $6.44, set on Jan 23, 2026 and 0.8% above the 52-week low of $1.32, near the bottom of the past year's range. ALT is down 63.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 72.3%.
Altimmune has posted a net loss over the last twelve months (EPS of -$0.71), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Altimmune
Company profileAltimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jerome Benedict Durso
- Headquarters
- Gaithersburg, MD
- Employees
- 57
- Website
- altimmune.com
Financial highlights
Full financialsIn fiscal 2025, Altimmune generated $41,000 in revenue, up 105.0% from fiscal 2024. Altimmune reported a net loss of $88.1 million, compared with a loss of $95.1 million a year earlier. Operating margin was -230461.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $41.00K | $20.00K | $426.00K | $-68.00K | $4.41M |
| Growth | +105.00% | -95.31% | +726.47% | -101.54% | -46.12% |
| Net income | $-88.09M | $-95.06M | $-88.45M | $-84.71M | $-97.09M |
| EPS (diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$16.33+1127.82%
- Strong buy 2
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.15 vs $-0.14
- Surprise
- -7.14%
ALT news
All ALT news- Altimmune to Participate in the 9th Annual Evercore Healthcare ConferenceGlobeNewswireALT, EVR
- Altimmune, Inc. Reports Third Quarter 2026 Financial Results and $480 million in Cash and InvestmentsNasdaq
- Altimmune (ALT) Q3 2026 Earnings Call TranscriptNasdaqALT, WSO.B
- Altimmune Announces Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire
- Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & HepatologyGlobeNewswire
- Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use DisorderGlobeNewswire
- Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026GlobeNewswire
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?NasdaqNVO, LLY, ALT, MDGL
Altimmune peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRLDPrelude Therapeutics Incorporated | 3.23 | -0.77% | $258.63M | vs ALT |
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs ALT |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs ALT |
| QTTBQ32 Bio Inc. | 8.34 | -1.65% | $249.57M | vs ALT |
| TTRXTurn Therapeutics Inc. | 8.10 | -6.31% | $247.49M | vs ALT |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs ALT |
| LFCRLifecore Biomedical Inc. | 6.39 | +0.31% | $242.22M | vs ALT |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs ALT |
Indexes, lists and sector
Altimmune stock FAQ
What is Altimmune's stock price today?
ALT last traded at $1.33 as of Nov 20, 4:00 PM EST, down 5.67% on the day. Prices are delayed at least 15 minutes.
Does Altimmune pay a dividend?
No. Altimmune does not currently pay a regular cash dividend.
Who is Altimmune's CEO?
Mr. Jerome Benedict Durso is the chief executive officer of Altimmune Inc., which has about 57 employees.
Has ALT ever split its stock?
Yes. The most recent ALT stock split was a 1-for-30 split on Sep 14, 2018.
What is the ALT 52-week high?
The 52-week high for ALT is $6.44 and the 52-week low is $1.32. The stock is currently 79.3% below its high.